[{"id":"2d640cff-e8d0-459a-ae6a-92adad2804d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03173950","created_at":"2022-04-11T23:54:29.961Z","updated_at":"2025-02-25T14:07:01.366Z","phase":"Phase 2","brief_title":"Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers","source_id_and_acronym":"NCT03173950","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCOR • FOXR2","pipe":"","alterations":" ","tags":["BCOR • FOXR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 07/13/2017","start_date":" 07/13/2017","primary_txt":" Primary completion: 07/15/2025","primary_completion_date":" 07/15/2025","study_txt":" Completion: 07/15/2026","study_completion_date":" 07/15/2026","last_update_posted":"2025-02-18"},{"id":"e7325205-5687-435e-9011-d1d353dd09cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05711992","created_at":"2023-02-03T15:00:13.912Z","updated_at":"2024-07-02T16:35:15.213Z","phase":"","brief_title":"Rare Embryonal Tumors of the Central Nervous System: International Registry","source_id_and_acronym":"NCT05711992","lead_sponsor":"Immune Oncology Research Institute","biomarkers":" BCOR • FOXR2","pipe":"","alterations":" ","tags":["BCOR • FOXR2"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 02/01/2033","primary_completion_date":" 02/01/2033","study_txt":" Completion: 02/01/2033","study_completion_date":" 02/01/2033","last_update_posted":"2024-03-12"}]